share_log

Esperion Therapeutics Analyst Ratings

Esperion Therapeutics Analyst Ratings

Esperion Therapeutics 分析
Benzinga ·  2023/10/02 06:29
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
10/02/2023 791.09% Needham → $9 Reiterates Buy → Buy
08/28/2023 2078.22% HC Wainwright & Co. → $22 Reiterates Buy → Buy
08/02/2023 791.09% Needham $10 → $9 Maintains Buy
06/26/2023 2078.22% HC Wainwright & Co. → $22 Reiterates Buy → Buy
06/15/2023 296.04% B of A Securities $1.25 → $4 Upgrades Underperform → Buy
06/01/2023 2078.22% HC Wainwright & Co. → $22 Reiterates → Buy
05/09/2023 890.1% Needham $12 → $10 Maintains Buy
04/18/2023 1088.12% Needham → $12 Reiterates → Buy
03/28/2023 1088.12% Needham → $12 Reiterates → Buy
03/20/2023 197.03% Morgan Stanley $9 → $3 Maintains Equal-Weight
03/16/2023 48.51% B of A Securities $8 → $1.5 Downgrades Neutral → Underperform
03/16/2023 1088.12% Needham $16 → $12 Maintains Buy
03/16/2023 2078.22% HC Wainwright & Co. → $22 Reiterates → Buy
03/07/2023 593.07% Credit Suisse $6.5 → $7 Upgrades Underperform → Neutral
03/06/2023 1385.15% JMP Securities → $15 Reiterates → Market Outperform
03/06/2023 1484.16% Needham $12 → $16 Maintains Buy
03/06/2023 2078.22% HC Wainwright & Co. → $22 Reiterates → Buy
02/27/2023 791.09% JP Morgan $8 → $9 Maintains Neutral
02/27/2023 692.08% B of A Securities → $8 Reinstates → Neutral
02/22/2023 1088.12% Needham → $12 Reiterates → Buy
02/03/2023 791.09% Morgan Stanley → $9 Upgrades Underweight → Equal-Weight
11/02/2022 791.09% Morgan Stanley $7 → $9 Maintains Underweight
08/03/2022 494.06% Credit Suisse $7 → $6 Downgrades Neutral → Underperform
07/15/2022 593.07% Morgan Stanley $5 → $7 Maintains Underweight
05/24/2022 197.03% Goldman Sachs $3.5 → $3 Maintains Sell
05/05/2022 — JP Morgan Upgrades Underweight → Neutral
03/10/2022 2078.22% HC Wainwright & Co. → $22 Initiates Coverage On → Buy
01/14/2022 494.06% Credit Suisse $8 → $6 Maintains Neutral
12/09/2021 1088.12% Needham $20 → $12 Maintains Buy
12/06/2021 395.05% Goldman Sachs $8 → $5 Maintains Sell
12/06/2021 692.08% Credit Suisse $11 → $8 Maintains Neutral
10/19/2021 989.11% Credit Suisse $28 → $11 Downgrades Outperform → Neutral
10/14/2021 989.11% Morgan Stanley → $11 Downgrades Equal-Weight → Underweight
08/04/2021 1583.17% Morgan Stanley $22 → $17 Maintains Equal-Weight
08/03/2021 11187.13% Needham $134 → $114 Maintains Strong Buy
05/05/2021 3464.36% Credit Suisse $45 → $36 Maintains Outperform
05/05/2021 2276.24% Northland Capital Markets $30 → $24 Maintains Market Perform
05/05/2021 2078.22% Morgan Stanley $30 → $22 Maintains Equal-Weight
05/05/2021 10890.1% JMP Securities $191 → $111 Maintains Market Outperform
05/05/2021 1880.2% Stifel $37 → $20 Downgrades Buy → Hold
03/11/2021 2870.3% Morgan Stanley → $30 Initiates Coverage On → Equal-Weight
02/24/2021 13167.33% Needham $150 → $134 Maintains Strong Buy
02/12/2021 2870.3% Jefferies $40 → $30 Downgrades Buy → Hold
02/09/2021 2276.24% Goldman Sachs → $24 Downgrades Neutral → Sell
01/15/2021 3365.35% B of A Securities → $35 Downgrades Buy → Neutral
11/10/2020 — Credit Suisse Upgrades Neutral → Outperform
10/15/2020 5048.51% B of A Securities $55 → $52 Maintains Buy
08/17/2020 5345.54% B of A Securities $60 → $55 Maintains Buy
08/11/2020 4355.45% Credit Suisse $83 → $45 Downgrades Outperform → Neutral
05/07/2020 6830.69% Jefferies $85 → $70 Maintains Buy
04/16/2020 4058.42% Northland Capital Markets $60 → $42 Maintains Market Perform
04/01/2020 4850.5% B of A Securities → $50 Initiates Coverage On → Buy
03/17/2020 — Citigroup Upgrades Neutral → Buy
02/28/2020 4553.47% JP Morgan $46 → $47 Maintains Neutral
02/24/2020 15543.56% Needham $144 → $158 Maintains Strong Buy
02/24/2020 — Northland Capital Markets Downgrades Outperform → Market Perform
02/14/2020 8018.81% Citigroup $73 → $82 Downgrades Buy → Neutral
09/18/2019 6830.69% Stifel $112 → $70 Maintains Buy
09/16/2019 4355.45% Goldman Sachs $55 → $45 Upgrades Sell → Neutral
05/29/2019 4850.5% Goldman Sachs → $50 Downgrades Neutral → Sell
04/26/2019 — Goldman Sachs Upgrades Sell → Neutral
03/13/2019 4553.47% JP Morgan $38 → $47 Upgrades Underweight → Neutral
12/13/2018 4355.45% Goldman Sachs → $45 Initiates Coverage On → Sell
10/16/2018 8018.81% BTIG → $82 Initiates Coverage On → Buy
日期 上行/下行 分析公司 目标价格变化 评级变化 上一次/当前评级
10/02/2023 791.09% 李约瑟 →$9 重申 购买→购买
2023年08月28日 2078.22% HC Wainwright公司 →$22 重申 购买→购买
08/02/2023 791.09% 李约瑟 $10→$9 维护 买
2023/06/26 2078.22% HC Wainwright公司 →$22 重申 购买→购买
2023/06/15 296.04% B of A证券 $1.25→$4 升级 表现不佳的→收购
06/01/2023 2078.22% HC Wainwright公司 →$22 重申 →购买
05/09/2023 890.1% 李约瑟 $12→$10 维护 买
04/18/2023 1088.12% 李约瑟 →$12 重申 →购买
03/28/2023 1088.12% 李约瑟 →$12 重申 →购买
03/20/2023 197.03% 摩根士丹利 $9→$3 维护 等重
03/16/2023 48.51% B of A证券 $8→$1.5 评级下调 中性→表现不佳
03/16/2023 1088.12% 李约瑟 $16→$12 维护 买
03/16/2023 2078.22% HC Wainwright公司 →$22 重申 →购买
03/07/2023 593.07% 瑞士信贷 $6.5→$7 升级 表现不佳的→中性
03/06/2023 1385.15% JMP证券 →$15 重申 →市场跑赢大盘
03/06/2023 1484.16% 李约瑟 $12→$16 维护 买
03/06/2023 2078.22% HC Wainwright公司 →$22 重申 →购买
02/27/2023 791.09% 摩根大通 $8→$9 维护 中性
02/27/2023 692.08% B of A证券 →$8 恢复 →中性
02/22/2023 1088.12% 李约瑟 →$12 重申 →购买
02/03/2023 791.09% 摩根士丹利 →$9 升级 重量不足的→等重
11/02/2022 791.09% 摩根士丹利 $7→$9 维护 体重不足
08/03/2022 494.06% 瑞士信贷 $7→$6 评级下调 中性→表现不佳
07/15/2022 593.07% 摩根士丹利 $5→$7 维护 体重不足
2022年05月24日 197.03% 高盛 $3.5→$3 维护 卖
05/05/2022 - 摩根大通 升级 减重→中性
03/10/2022 2078.22% HC Wainwright公司 →$22 开始承保 →购买
2022年01月14日 494.06% 瑞士信贷 $8→$6 维护 中性
12/09/2021 1088.12% 李约瑟 $20→$12 维护 买
12/06/2021 395.05% 高盛 $8→$5 维护 卖
12/06/2021 692.08% 瑞士信贷 $11→$8 维护 中性
10/19/2021 989.11% 瑞士信贷 $28→$11 评级下调 跑赢→中性
10/14/2021 989.11% 摩根士丹利 →$11 评级下调 等重→减码
08/04/2021 1583.17% 摩根士丹利 $22→$17 维护 等重
08/03/2021 11187.13% 李约瑟 $134→$114 维护 强势购买
05/05/2021 3464.36% 瑞士信贷 $45→$36 维护 跑赢大盘
05/05/2021 2276.24% 北国资本市场 $30→$24 维护 市场表现
05/05/2021 2078.22% 摩根士丹利 $30→$22 维护 等重
05/05/2021 10890.1% JMP证券 $191→$111 维护 市场表现强于大盘
05/05/2021 1880.2% Stifel $37→$20 评级下调 购买→Hold
03/11/2021 2870.3% 摩根士丹利 →$30 开始承保 →等重
02/24/2021 13167.33% 李约瑟 $150→$134 维护 强势购买
02/12/2021 2870.3% 杰富瑞 $40→$30 评级下调 购买→Hold
02/09/2021 2276.24% 高盛 →$24 评级下调 中性→销售
2021/01/15 3365.35% B of A证券 →$35 评级下调 购买→中性
11/10/2020 - 瑞士信贷 升级 中性→表现优异
10/15/2020 5048.51% B of A证券 $55→$52 维护 买
2020/08/17 5345.54% B of A证券 $60→$55 维护 买
2020年08月11日 4355.45% 瑞士信贷 $83→$45 评级下调 跑赢→中性
05/07/2020 6830.69% 杰富瑞 $85→$70 维护 买
04/16/2020 4058.42% 北国资本市场 $60→$42 维护 市场表现
04/01/2020 4850.5% B of A证券 →$50 开始承保 →购买
03/17/2020 - 花旗集团 升级 中性→购买
02/28/2020 4553.47% 摩根大通 $46→$47 维护 中性
02/24/2020 15543.56% 李约瑟 $144→$158 维护 强势购买
02/24/2020 - 北国资本市场 评级下调 跑赢→市场表现
02/14/2020 8018.81% 花旗集团 $73→$82 评级下调 购买→中性
2019年09月18日 6830.69% Stifel $112→$70 维护 买
2019/09/16 4355.45% 高盛 $55→$45 升级 卖出→中性
2019年05月29日 4850.5% 高盛 →$50 评级下调 中性→销售
2019年04月26日 - 高盛 升级 卖出→中性
2019/03/13 4553.47% 摩根大通 $38→$47 升级 减重→中性
2018年12月13日 4355.45% 高盛 →$45 开始承保 →销售
2018年10月16日 8018.81% BTIG →$82 开始承保 →购买

What is the target price for Esperion Therapeutics (ESPR)?

Esperion Treateutics(ESPR)的目标价格是多少？

The latest price target for Esperion Therapeutics (NASDAQ: ESPR) was reported by Needham on October 2, 2023. The analyst firm set a price target for $9.00 expecting ESPR to rise to within 12 months (a possible 791.09% upside). 22 analyst firms have reported ratings in the last year.

Needham于2023年10月2日报道了Esperion治疗公司(纳斯达克：ESPR)的最新目标价。这家分析公司将目标价定为9美元，预计每股收益将在12个月内升至(可能上涨791.09%)。过去一年，有22家分析公司公布了评级。

What is the most recent analyst rating for Esperion Therapeutics (ESPR)?

Esperion Treateutics(ESPR)的最新分析师评级是什么？

The latest analyst rating for Esperion Therapeutics (NASDAQ: ESPR) was provided by Needham, and Esperion Therapeutics reiterated their buy rating.

Needham提供了对Esperion Treateutics(纳斯达克代码：ESPR)的最新分析师评级，Esperion Treateutics重申了他们的买入评级。

When is the next analyst rating going to be posted or updated for Esperion Therapeutics (ESPR)?

Esperion Treeutics(ESPR)的下一次分析师评级将于何时发布或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Esperion Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Esperion Therapeutics was filed on October 2, 2023 so you should expect the next rating to be made available sometime around October 2, 2024.

分析师在进行了广泛的研究后得出股票评级，其中包括查阅公共财务报表，与Esperion Treeutics的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Esperion治疗公司的上一次评级是在2023年10月2日提交的，所以你应该预计下一次评级将在2024年10月2日左右的某个时候提供。

Is the Analyst Rating Esperion Therapeutics (ESPR) correct?

分析师对Esperion Treeutics(ESPR)的评级正确吗？

While ratings are subjective and will change, the latest Esperion Therapeutics (ESPR) rating was a reiterated with a price target of $0.00 to $9.00. The current price Esperion Therapeutics (ESPR) is trading at is $1.01, which is within the analyst's predicted range.

虽然评级是主观的，并将发生变化，但最新的Esperion治疗(ESPR)评级被重申，目标价在0.00美元至9.00美元之间。Esperion Treateutics(ESPR)目前的交易价格为1.01美元，在分析师的预测范围内。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发